Spots Global Cancer Trial Database for gorlin syndrome

Every month we try and update this database with for gorlin syndrome cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS)	NCT00957229	Basal Cell Nevu... Gorlin Syndrome	GDC-0449	35 Years - 75 Years	UCSF Benioff Children's Hospital Oakland
CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome	NCT04893486	BCCs in Gorlin ...	PTX-022 Vehicle compara...	18 Years -	Palvella Therapeutics, Inc.
Nevoid Basal Cell Carcinomas in Gorlin Syndrome	NCT05898347	Basal Cell Carc... Gorlin Syndrome	Active surveill...	6 Years - 17 Years	Oslo University Hospital
Two Studies to Determine if Verteporfin PDT is Effective & Safe in Treating Multiple Basal Cell Carcinoma of the Skin.	NCT00049959	Basal Cell Carc... Nevoid Basal Ce... Gorlin Syndrome	verteporfin PDT	18 Years - 90 Years	QLT Inc.
Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients	NCT02762084	Basal Cell Nevu...	Patidegib Vehicle gel	18 Years - 85 Years	PellePharm, Inc.
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome	NCT06050122	Gorlin Syndrome	Patidegib Topic... Patidegib Topic...	18 Years -	Sol-Gel Technologies, Ltd.
Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)	NCT04308395	Basal Cell Nevu...	Patidegib Topic...	18 Years -	Sol-Gel Technologies, Ltd.
Two Studies to Determine if Verteporfin PDT is Effective & Safe in Treating Multiple Basal Cell Carcinoma of the Skin.	NCT00049959	Basal Cell Carc... Nevoid Basal Ce... Gorlin Syndrome	verteporfin PDT	18 Years - 90 Years	QLT Inc.
Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study	NCT05463757	Basal Cell Carc... Locally Advance... Metastatic Basa... Gorlin Syndrome Basal Cell Nevu... Carcinoma, Basa... Carcinoma Basal Cell Tumo... Skin Cancer Neoplasm of Ski... Neoplasms, Basa...	Vismodegib Sonidegib	-	Maastricht University Medical Center
Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)	NCT03703310	Basal Cell Nevu...	Patidegib Topic... Patidegib Topic...	18 Years -	PellePharm, Inc.
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome	NCT06050122	Gorlin Syndrome	Patidegib Topic... Patidegib Topic...	18 Years -	Sol-Gel Technologies, Ltd.
Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas	NCT02828111	Basal Cell Carc...	Patidegib Vehicle gel	18 Years - 85 Years	PellePharm, Inc.
Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas	NCT02828111	Basal Cell Carc...	Patidegib Vehicle gel	18 Years - 85 Years	PellePharm, Inc.
Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)	NCT01350115	Basal Cell Carc... Gorlin Syndrome Nevoid Basal Ce...	LDE225 Placebo	18 Years -	Novartis
To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS)	NCT00957229	Basal Cell Nevu... Gorlin Syndrome	GDC-0449	35 Years - 75 Years	UCSF Benioff Children's Hospital Oakland
CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome	NCT04893486	BCCs in Gorlin ...	PTX-022 Vehicle compara...	18 Years -	Palvella Therapeutics, Inc.
Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)	NCT04308395	Basal Cell Nevu...	Patidegib Topic...	18 Years -	Sol-Gel Technologies, Ltd.

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: